Marshall Helen, Clarke Michelle, Rasiah Kavita, Richmond Peter, Buttery Jim, Reynolds Graham, Andrews Ross, Nissen Michael, Wood Nick, McIntyre Peter
From the *Robinson Research Institute, Discipline of Paediatrics, School of Paediatrics and Reproductive Health, University of Adelaide; †Vaccinology and Immunology Research Trials Unit, Department of Paediatrics, Women's and Children's Hospital, South Australia, Australia; ‡School of Paediatrics & Child Health, University of Western Australia; §Princess Margaret Hospital for Children; ¶Wesfarmer's Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Western Australia, Australia; **SAEFVIC, Murdoch Children's Research Institute, Paediatric Infectious Diseases, Department of Paediatrics, Monash Children's Hospital, Monash University, Victoria, Australia; ††Department of Paediatrics and Child Health, Medical School, Australian National University, Canberra, Australia; ‡‡Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia; §§Qpid Laboratory, Queensland Children's Medical Research Institute, Royal Children's Hospital, Brisbane, Australia; and ¶¶National Centre for Immunisation Research and Surveillance, Kids Research Institute, Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Pediatr Infect Dis J. 2015 Apr;34(4):339-45. doi: 10.1097/INF.0000000000000577.
Australia recently experienced its worst pertussis epidemic since introduction of pertussis vaccine into the National Immunisation Program. This study aimed to determine factors associated with severe pertussis in hospitalized children during an epidemic using a novel pertussis severity scoring (PSS) system.
This prospective, observational, multicenter study enrolled children hospitalized with laboratory confirmed pertussis from 8 tertiary pediatric hospitals during a 12 month period (May 2009-April 2010). Variables assessed included demographics, clinical symptoms and relevant medical and immunization history. Cases were scored using objective clinical findings with cases classified as either severe (PSS > 5) or not severe (PSS ≤ 5). Logistic regression models were used to predict variables associated with severe disease.
One hundred twenty hospitalized children 0-17 years of age were enrolled with a median PSS of 5 (interquartile range 3-7). Most (61.7%) were classified as not severe with 38.3% (46/120) severe. Most severe cases (54.3%) were <2 months of age. Presence of coinfection [odds ratio (OR): 4.82, CI: 1.66-14.00], <2 months old (OR: 4.76, CI: 1.48-15.32), fever >37.5°C (OR: 5.97, CI: 1.19-29.96) and history of prematurity (OR: 5.00, CI: 1.27-19.71) were independently associated with severe disease. A total of 70 cases in children ≥2 months of age, almost a third (n = 23) had not received pertussis vaccine.
Most severe pertussis occurred in young, unimmunized infants, although severe disease was also observed in children >12 months of age and previously vaccinated children. Children admitted with pertussis with evidence of coinfection, history of prematurity or fever on presentation need close monitoring.
自百日咳疫苗被纳入国家免疫规划以来,澳大利亚最近经历了最严重的百日咳疫情。本研究旨在使用一种新的百日咳严重程度评分(PSS)系统,确定疫情期间住院儿童中与严重百日咳相关的因素。
这项前瞻性、观察性、多中心研究在12个月期间(2009年5月至2010年4月),纳入了8家三级儿科医院中实验室确诊为百日咳的住院儿童。评估的变量包括人口统计学、临床症状以及相关的医疗和免疫史。根据客观临床发现对病例进行评分,病例分为严重(PSS>5)或不严重(PSS≤5)。采用逻辑回归模型预测与严重疾病相关的变量。
共纳入120名0至17岁的住院儿童,PSS中位数为5(四分位间距3至7)。大多数(61.7%)被分类为不严重,38.3%(46/120)为严重。大多数严重病例(54.3%)年龄小于2个月。合并感染(比值比[OR]:4.82,可信区间[CI]:1.66至14.00)、年龄小于2个月(OR:4.76,CI:1.48至15.32)、发热>37.5°C(OR:5.97,CI:1.19至29.96)和早产史(OR:5.00,CI:1.27至19.71)与严重疾病独立相关。在70例年龄≥2个月的儿童中,近三分之一(n = 23)未接种百日咳疫苗。
大多数严重百日咳发生在未接种疫苗的幼儿中,尽管在12个月以上儿童和既往接种过疫苗的儿童中也观察到严重疾病。因百日咳入院且有合并感染证据、早产史或就诊时发热的儿童需要密切监测。